SEATTLE, Jan. 27, 2026 /PRNewswire/ -- As modern homes continue to evolve, consumers are increasingly looking for appliances that strike the right balance between performance, design, and practicality. Tineco, a global leader in intelligent floor care solutions, brings this philosophy to life through a refined product portfolio designed to support modern living with smarter, more balanced cleaning experiences.
By combining advanced technology with user-centric design, Tineco's latest range addresses a broad spectrum of household needs — from effective wet-dry floor care to effortless cordless vacuuming — all while remaining intuitive and accessible for everyday use.
Designed for effortless cleaning in hard-to-reach spaces
For homes where dust and debris tend to accumulate under furniture and along edges, FLOOR ONE Stretch S6 makes thorough floor cleaning simpler and more efficient. Its 180° lay-flat design slides seamlessly beneath beds, sofas, and low cabinetry, helping remove dust and allergens from areas that are often overlooked during routine cleaning.
Triple-sided edge cleaning reaches as close as 0.2 inches from skirting boards, while up to 40 minutes of runtime supports uninterrupted cleaning across rooms. Powered by iLoop™ Technology, the Stretch S6 automatically adjusts performance based on the mess detected, allowing users to focus on their space rather than the settings. After cleaning, the FlashDry™ Self-Cleaning System rinses and dries the entire unit, keeping it fresh and ready for the next use.
→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $429 and savings of 52%.
Designed for flexible, whole-home cleaning without compromise
For households seeking one tool that adapts easily to different cleaning tasks, FLOOR ONE Switch S7 Stretch delivers true multi-function versatility. Designed as a 5-in-1 solution, it transitions effortlessly between floor washing and vacuuming, handling wet and dry messes, hard floors, furniture surfaces, and hard-to-reach crevices throughout the house.
At the core of this flexibility is SwitchPro Motor, which enables smooth switching between modes without interrupting cleaning. DualBlock Anti-Tangle and ZeroTangle brush designs work together to prevent hair and pet fur from wrapping around the brush, ensuring consistent performance with minimal maintenance. After use, the upgraded FlashDry™ Self-Cleaning System uses 85°C heated water and hot air to thoroughly clean and dry internal components, delivering a more hygienic and hassle-free ownership experience.
→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $849 and savings of 29%.
Designed for everyday performance with an artistic touch
For households that value both performance and design, FLOOR ONE S9 Artist brings together full-featured floor care and an elegant, artist-inspired aesthetic. Built for high-efficiency everyday use, it delivers smooth steering, effortless manoeuvrability, and edge-to-edge reach, allowing users to move easily from room to room.
SmoothDrive™ Technology supports responsive handling, while a low-profile, 180° lay-flat design provides access beneath furniture. A dynamic display with shifting 3D lighting, combined with an LED headlight, offers clear, real-time guidance throughout the cleaning process. With up to 75 minutes of runtime, the S9 Artist is designed for uninterrupted cleaning sessions that feel intuitive and refined.
→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $899 and savings of 25%.
For smaller homes or shorter cleaning routines, FLOOR ONE S7 Artist offers a streamlined alternative, delivering up to 50 minutes of runtime and the same design-led experience, just without the SmoothDrive™ system.
→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $679 and savings of 24%.
Designed for low-maintenance, worry-free vacuuming
For busy households that want to minimise hands-on maintenance, PURE ONE Station 5 transforms cordless vacuuming into a cleaner, more automated routine. Its 3-in-1 Smart Station charges, stores, and automatically empties the dustbin, holding up to 45 days of debris without manual contact.
With 175W of suction power, a 120° wide green LED headlight, and a ZeroTangle brush head, the Station 5 captures everything from fine dust to pet hair across floors and elevated surfaces. Up to 70 minutes of runtime supports whole-home cleaning, while a 2-in-1 crevice brush with an extendable tube makes it easier to reach shelves, curtains, ceiling corners, and other high or narrow spaces. The result is a practical, efficient solution that fits seamlessly into everyday living.
→ Available via Amazon from January 27 to February 1, with a promotional price of AUD $559 and savings of 30%.
About Tineco
Tineco ("tin-co") was founded in 1998 with its first product launch as a vacuum cleaner and, in 2019, pioneered the first-ever smart vacuum. Today, the brand has evolved into a global leader in intelligent appliances spanning floor care, kitchen, and personal care categories. With a growing user base of over 23 million households and availability in approximately 30 countries worldwide, Tineco remains committed to its brand vision of making life easier through smart technology and continuous innovation. For more information, visit au.tineco.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Tineco Brings Smarter Floor Care Solutions to Modern Homes This Winter
- Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.
- License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset.
- Boehringer receives global rights to the asset, excluding greater China; Simcere is eligible to receive payments of up to EUR 1,058 million
SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).
Globally, it is estimated that more than three million people are affected by IBD, a lifelong, progressive condition leading to frequent hospitalization and surgeries, significantly impacting patients' quality of life. Current medical options cannot fully prevent or reverse these complications, leaving a clear unmet need. Through this partnership, Boehringer and Simcere aim to advance an innovative approach to potentially redefine treatment possibilities and improve outcomes for patients worldwide.
SIM0709 is a long-acting humanized bispecific antibody developed by Simcere using its proprietary multi-specific antibody platform. It simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), thereby blocking two core pathways that drive the onset and progression of IBD. Both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.
Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim said, "In IBD, too many patients continue to progress and experience severe complications despite currently available anti-inflammatory therapies. We are excited to join forces with Simcere to accelerate the development of this therapeutic as a potential life changing option for patients living with IBD."
"Simcere's bispecific antibody SIM0709 was engineered with our proprietary multi-specific antibody platform with first-in-class potential for IBD treatment. Partnering with Boehringer Ingelheim, with its long‑term commitment and deep expertise in immunology, positions the compound for rigorous global development," said Gaobo Zhou, Chief Investment Officer, Simcere Pharmaceutical Group. "Together we aim to accelerate the clinical development and advance a treatment option that could improve outcomes for patients world-wide affected by IBD."
Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, regulatory and sales milestones up to EUR 1,058 million, as well as royalties on net sales outside of the Greater China territory.
This marks Simcere's second out- licensing transaction in the autoimmune field. As of January 2026, Simcere has completed a total of 5 out-licensing deals for its self-developed novel drug technologies, with a total potential transaction value of approximately $4.6 billion.
About Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited（2096.HK）is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore areas with significant unmet needs, and our mission is For patients, for life. Driven by our in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many innovative companies and research institutes. Learn more at www.simcere.com.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
SHANGHAI, Jan. 27, 2026 /PRNewswire/ -- Simcere Pharmaceutical Group Ltd. ("Simcere") (HKEX: 2096) and Boehringer Ingelheim, today announced a license and collaboration agreement to develop SIM0709, a pre-clinical TL1A/IL23p19 bispecific antibody from Simcere, for the treatment of inflammatory bowel disease (IBD).
Globally, it is estimated that more than three million people are affected by IBD, a lifelong, progressive condition leading to frequent hospitalization and surgeries, significantly impacting patients' quality of life. Current medical options cannot fully prevent or reverse these complications, leaving a clear unmet need. Through this partnership, Boehringer and Simcere aim to advance an innovative approach to potentially redefine treatment possibilities and improve outcomes for patients worldwide.
SIM0709 is a long-acting humanized bispecific antibody developed by Simcere using its proprietary multi-specific antibody platform. It simultaneously targets tumor necrosis factor ligand superfamily member 15 (TL1A) and interleukin-23 (IL-23), thereby blocking two core pathways that drive the onset and progression of IBD. Both in vitro primary cell studies and in vivo animal studies, SIM0709 demonstrated superior synergistic efficacy, even outperforming the combination of the two corresponding monotherapies.
Carine Boustany, US Innovation Unit Site Head and Global Head of Immunology and Respiratory Diseases at Boehringer Ingelheim said, "In IBD, too many patients continue to progress and experience severe complications despite currently available anti-inflammatory therapies. We are excited to join forces with Simcere to accelerate the development of this therapeutic as a potential life changing option for patients living with IBD."
"Simcere's bispecific antibody SIM0709 was engineered with our proprietary multi-specific antibody platform with first-in-class potential for IBD treatment. Partnering with Boehringer Ingelheim, with its long‑term commitment and deep expertise in immunology, positions the compound for rigorous global development," said Gaobo Zhou, Chief Investment Officer, Simcere Pharmaceutical Group. "Together we aim to accelerate the clinical development and advance a treatment option that could improve outcomes for patients world-wide affected by IBD."
Under the terms of the agreement Boehringer receives global rights to the asset, excluding greater China. Simcere is eligible to receive an upfront payment as well as success-based development, regulatory and sales milestones up to EUR 1,058 million, as well as royalties on net sales outside of the Greater China territory.
This marks Simcere's second out- licensing transaction in the autoimmune field. As of January 2026, Simcere has completed a total of 5 out-licensing deals for its self-developed novel drug technologies, with a total potential transaction value of approximately $4.6 billion.
About Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited（2096.HK）is a pharmaceutical company driven by innovation and focusing on four therapeutic areas including Neuroscience, Oncology, Autoimmune Diseases and Anti-infection. We proactively explore areas with significant unmet needs, and our mission is For patients, for life. Driven by our in-house R&D efforts and synergistic innovation, Simcere has established strategic cooperation partnerships with many innovative companies and research institutes. Learn more at www.simcere.com.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
